L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Northwestern Mutual, presenting sponsor of the Rose Bowl Game, today announced that its float in the 127th Rose Parade presented by Honda in Pasadena on Jan. 1, 2016, will support the fight against childhood cancer.
The theme of this year’s parade is Find Your Adventure. Northwestern Mutual will dedicate its float design to the greatest adventure and dream of 13-year-old Peyton Richardson of Sugar Land, Texas, who is in treatment for acute lymphocytic leukemia (ALL). Northwestern Mutual is committed to raising awareness, accelerating the search for cures to childhood cancer and providing support to families battling the disease.
Peyton, an aspiring ballerina, would like to see the performances of the distinguished ballet companies of the world and have a ballet lesson with one of their principal dancers. Peyton’s adventure will be brought to life in flowers by Fiesta Parade Floats.
To view the multimedia release go to:
http://www.multivu.com/players/English/7422154-northwestern-mutual-rose-bowl/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are once again teaming up to hit home runs for prostate cancer research and encourage fans to “Keep Dad in the Game” as part of the yearly celebration of Father’s Day and annual Home Run Challenge.
This year Joe Torre, MLB’s Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encourages baseball fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”
“Joe has been a great partner in our progress toward improved treatment outcomes and an eventual cure,” said PCF Founder and Chairman Mike Milken. “His work as well as those by MLB and all 30 Clubs has helped us raise more than $45 million for research programs that are saving thousands of lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7729251-pcf-and-mlb-prostate-home-run-challenge/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Turning your clocks ahead an hour on March 8 for the start of Daylight Savings Time may be known as the unofficial start to spring, but for many, it’s known as the day we lose an hour of sleep. As you prepare to change your clocks on Sunday, take that opportunity to evaluate your sleeping habits. The loss of that hour of sleep can turn minor sleep issues into major ones.
“When we move our clock forward or backward, our internal clock becomes out of sync with the external time,” says Dr. Daniel Shade, Board Certified Sleep Specialist and Director of the AHN Sleep Disorders Center. “The best way to combat this is to expose ourselves to light and let our bodies resynchronize.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447951-remworks-daylight-savings-sleep-coach/
The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education facility to expand their services further. These expansions are part of constant improvements that have been occurring for the last 15 years, alongside high quality service.
The area of the clinic has increased by ten-fold to approximately 1800 m2 during the years. Moreover, the oral surgery division was opened in 2015, so eight dental treatment rooms and four oral surgery rooms are now in place today. All of the surgery rooms can serve ambulatory oral surgery treatments. The ImplantCenter is unique in Hungarian private dentistry because they can implement more complex treatments in the framework of one-day oral surgery procedure. This is due to the big and fully equipped operating room opened in November 2017. As part of the service, the ImplantCenter offers one and two-bed private rooms with medical supervision to their patients after each surgery.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8274651-implantcenter-hungarian-dental-service/
Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL.
Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision.
To view the multimedia release go to:
http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
